BioSpace News Archive

DexCom, Inc. announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023.

Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh

Labcorp, a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2023 before the market opens on Thursday, October 26, 2023.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases, announced the appointments of Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer.

AbbVie announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax plus dexamethasone for patients with t-positive relapsed or refractory multiple myeloma who have received two or more prior treatments.

Ocugen, Inc. announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held October 3-5, 2023 in Boston, Mass.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced financial results and highlights for the first half of 2023, ended June 30th.

Promontory Therapeutics Inc., a clinical stage biotechnology company advancing immunogenic small molecule approaches in oncology, has become the first international company to gain membership in the Paris-Saclay Cancer Center, an emerging European hub for cancer research and innovation.

Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.

Maravai LifeSciences Holdings, Inc. hosted its 2023 Investor R&D Day featuring presentations by Trey Martin, Chief Executive Officer, and other members of the Maravai leadership team that showcased the company’s strong foundation for growth, key differentiators, innovations, and attractive long-term growth outlook.